{
    "title": "103_hr916",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Prescription Drug Prices Review \nBoard Act of 1993''.\n\nSEC. 2. ESTABLISHMENT.\n\n    There is established in the Food and Drug Administration a board to \nbe known as the Patented Medicine Prices Review Board (in this Act \nreferred to as the ``Board'').\n\nSEC. 3. MEMBERSHIP.\n\n    (a) Number and Appointment.--The Board shall be composed of 5 \nmembers appointed by the President, by and with the advice and consent \nof the Senate, from among individuals--\n            (1) who are recognized experts in the fields of consumer \n        advocacy, medicine, pharmacology, pharmacy, and prescription \n        drug reimbursement; and\n            (2) who have not worked in the pharmaceutical industry \n        during the 1-year period ending on the date of appointment.\n    (b) Initial Appointments.--Initial appointments under subsection \n(a) shall be made not later than 90 days after the date of the \nenactment of this Act.\n    (c) Terms.--\n            (1) In general.--Except as provided in paragraphs (2) and \n        (3), each member shall be appointed for a term of 5 years.\n            (2) Terms of initial appointees.--As designated by the \n        President at the time of appointment, of the members first \n        appointed--\n                    (A) 1 member shall be appointed for a term of 1 \n                year;\n                    (B) 1 member shall be appointed for a term of 2 \n                years;\n                    (C) 1 member shall be appointed for a term of 3 \n                years;\n                    (D) 1 member shall be appointed for a term of 4 \n                years; and\n                    (E) 1 member shall be appointed for a term of 5 \n                years.\n            (3) Vacancies.--A vacancy in the Board shall be filled in \n        the manner in which the original appointment was made. Any \n        member appointed to fill a vacancy occurring before the \n        expiration of the term for which the member's predecessor was \n        appointed shall be appointed only for the remainder of that \n        term. A member may serve after the expiration of the member's \n        term until a successor has taken office.\n    (d) Initial Meeting.--The initial meeting of the Board shall be \nheld not later than 90 days after the date on which the first \nappointments of the members have been completed.\n    (e) Chairperson.--The President shall designate 1 member of the \nBoard to serve as the chairperson.\n    (f) Basic Pay.--\n            (1) In general.--Members shall be paid at a rate not to \n        exceed the daily equivalent of the maximum annual rate of basic \n        pay payable for grade GS-18 of the General Schedule under \n        section 5332 of title 5, United States Code, for each day \n        during which the members are engaged in the actual performance \n        of the duties of the Board.\n            (2) Travel expenses.--Members shall receive travel \n        expenses, including per diem in lieu of subsistence, in \n        accordance with sections 5702 and 5703 of title 5, United \n        States Code.\n\nSEC. 4. DIRECTOR AND STAFF.\n\n    (a) Director.--The Board shall have a director who shall be \nappointed by the chairperson, subject to rules prescribed by the Board.\n    (b) Staff.--The chairperson may appoint and fix the pay of such \nadditional personnel as the chairperson considers appropriate, subject \nto rules prescribed by the Board.\n    (c) Applicability of Certain Civil Service Laws.--The director and \nstaff of the Board shall be appointed subject to the provisions of \ntitle 5, United States Code, governing appointments in the competitive \nservice, and shall be paid in accordance with the requirements of \nchapter 51 and subchapter III of chapter 53 of such title relating to \nclassification and General Schedule pay rates; except that an \nindividual so appointed may not receive pay in excess of the maximum \nannual rate of basic pay payable for grade GS-15 of the General \nSchedule.\n\nSEC. 5. REGULATION OF PRESCRIPTION DRUG PRICING.\n\n    (a) Annual Information Requirement.--The Board shall require each \npatentee of a prescription drug to provide the Board with information \non an annual basis--\n            (1) identifying the type of prescription drug sold by the \n        patentee; and\n            (2) identifying the price at which the prescription drug is \n        being sold in the United States.\nThe Board shall also require each such patentee to provide the Board \nwith information describing the costs of producing and marketing the \nprescription drug for sale in the United States. Such information shall \nbe provided at a level of specificity necessary for the Board to make \nits determination under subsection (b).\n    (b) Decrease in Length of Patent Term.--\n            (1) In general.--The Board shall decrease the length of a \n        term of a patent issued under section 151 of title 35, United \n        States Code, for a prescription drug, after notice and an \n        opportunity for a hearing, if the patentee of such drug charges \n        an excessive price for such drug. If the patentee charged an \n        excessive price for a drug which has gone off patent, the Board \n        may select another drug of the patentee to have its length of \n        patent term reduced.\n            (2) Excessive price.--\n                    (A) In general.--For purposes of paragraph (1), the \n                term ``excessive price'' means the average price \n                charged by the patentee for a prescription drug during \n                the calendar year preceding the date on which the Board \n                gives notice to the patentee under paragraph (1), if \n                such price for such calendar year, adjusted for cost-\n                of-living, as determined by the Board, exceeds the \n                average price for such drug charged by the patentee for \n                the calendar year preceding such year in an amount \n                determined by the Board to be excessive under \n                subparagraph (B).\n                    (B) Excessive amount.--In determining if an amount \n                of increase in a drug price is excessive, the Board \n                shall consider--\n                            (i) the average price at which the patentee \n                        sold the drug during the 5-year period ending \n                        on the date on which the Board gives notice to \n                        the patentee under paragraph (1);\n                            (ii) the average prices of other \n                        prescription drugs in the same therapeutic \n                        class sold in the United States during such \n                        period;\n                            (iii) the average price at which the \n                        prescription drug and other prescription drugs \n                        in the same therapeutic class have been sold in \n                        countries other than the United States during \n                        such period;\n                            (iv) the costs associated with producing \n                        and marketing the prescription drug during such \n                        period and the value of any support provided by \n                        Federal agencies, the value of any tax benefit \n                        provided to the patentee in the development of \n                        the drug, the amount of compensation provided \n                        to officers of the patentee, and other factors \n                        determinative as to the true cost of \n                        production; and\n                            (v) if the price of the drug exceeds the \n                        CPI increase percentage (as defined in section \n                        215(i) of the Social Security Act) by more than \n                        2 percent.\n            (3) Length of term decrease.--The Board shall determine the \n        length of the decrease of a term of a patent for a prescription \n        drug described in paragraph (1).\n    (c) Authority To Recapture Certain Tax Benefits.--\n            (1) In general.--If the Board determines, after notice and \n        an opportunity for a hearing, that the patentee of any \n        prescription drug charges an excessive price for such drug, the \n        Board may require the recapture of tax benefits provided to the \n        patentee with respect to such drug.\n            (2) Recapture.--\n                    (A) In general.--If the Board requires the \n                recapture of tax benefits with respect to any \n                prescription drug, the patentee's tax under chapter 1 \n                of the Internal Revenue Code of 1986 for each taxable \n                year specified by the Board shall be increased by the \n                aggregate of the recapture amounts with respect to \n                sales of such drug during such taxable year.\n                    (B) Recapture amount.--For purposes of subparagraph \n                (A), the recapture amount with respect to the sale of \n                any prescription drug is the lesser of--\n                            (i) the portion of the price of such drug \n                        which the Board determines is excessive, or\n                            (ii) the amount which the Board determines \n                        is such sales pro rata share of the tax \n                        benefits received by the patentee in connection \n                        with the research for, and development of, such \n                        drug.\n            (3) No credits against tax, etc.--Any increase in tax by \n        reason of this subsection shall not be treated as a tax imposed \n        by chapter 1 of such Code for purposes of determining--\n                    (A) the amount of any credit under subpart A, B, D, \n                or G of part IV of subchapter A of such chapter, or\n                    (B) the minimum tax under section 55 of such Code.\n    (d) Manufacture and Sale of Drugs.--If the Board determines, after \nnotice and an opportunity for a hearing, that the patentee of any \nprescription drug charges an excessive price for such drug, the Board \nmay, either directly or by contract, manufacture and sell such drug.\n    (e) Increase in Length of Patent Term.--\n            (1) In general.--Upon application of the patentee, the \n        Board may increase the length of a term of a patent issued \n        under section 151 of title 35, United States Code, for a \n        prescription drug, if--\n                    (A) the Board determines that the patentee of such \n                drug has not charged an excessive price for such drug \n                during the 5-year period ending on the date the \n                patentee applies to the Board, as determined by the \n                Board using rules similar to the rules applicable under \n                subsection (b); and\n                    (B) the patentee provides assurances satisfactory \n                to the Board that it will not charge an excessive price \n                for such drug for any period during the extension of \n                the term.\n            (2) Length of term increase.--\n                    (A) In general.--Subject to subparagraph (B), the \n                Board shall determine the length of the increase of a \n                term of a patent for a prescription drug described in \n                paragraph (1).\n                    (B) Limitation.--The Board may not increase the \n                length of a term of such patent in excess of 10 percent \n                of the length of the original term of such patent.\n    (f) Regulations.--\n            (1) In general.--Not later than 1 year after the date of \n        the initial meeting held under section 3(e), the Board shall \n        develop regulations to carry out subsections (a), (b), (c), \n        (d), and (e).\n            (2) Notice and comment requirement.--The regulations \n        developed under paragraph (1) shall be issued in accordance \n        with the notice and comment procedures established under \n        section 553 of title 5, United States Code.\n    (g) Definitions.--For purposes of this section, the following \ndefinitions apply:\n            (1) Patentee.--The term ``patentee'' has the meaning given \n        such term in section 100(d) of title 35, United States Code.\n            (2) Prescription drug.--The term ``prescription drug'' \n        means a drug (as defined in section 201(g)(1) of the Federal \n        Food, Drug, and Cosmetic Act (21 U.S.C. 321 (g)(1))) which is \n        subject to regulation under section 503(b) of such Act.\n\nSEC. 6. PROVISION OF REPORT TO FEDERAL AGENCIES RELATING TO \n              PRESCRIPTION DRUGS SOLD AT EXCESSIVE PRICES.\n\n    (a) In General.--The Board shall provide on an annual basis to each \nFederal agency which dispenses or makes payments for the dispensing of \nprescription drugs a report containing--\n            (1) a list of each prescription drug which is sold at an \n        excessive price, as determined by the Board under section \n        5(b)(2);\n            (2) recommendations to the Federal agency against \n        dispensing or making payments for the dispensing of the \n        prescription drug; and\n            (3) recommendations to the Federal agency to substitute the \n        drug with a similar prescription drug which is not sold at an \n        excessive price.\n    (b) Prescription Drug Defined.--For purposes of this section, the \nterm ``prescription drug'' has the meaning given such term in section \n5(e)(2).\n\nSEC. 7. POWERS.\n\n    (a) Obtaining Official Data.--The chairperson may secure directly \nfrom any Federal agency information necessary to enable the Board to \ncarry out its duties. Upon request of the chairperson, the head of the \nagency shall furnish such information to the Board to the extent such \ninformation is not prohibited from disclosure by law.\n    (b) Mails.--The Board may use the United States mails in the same \nmanner and under the same conditions as other Federal agencies.\n    (c) Administrative Support Services.--Upon the request of the \nchairperson, the Administrator of General Services shall provide to the \nBoard on a reimbursable basis, the administrative support services \nnecessary for the Board to carry out its duties.\n    (d) Contract Authority.--The chairperson may contract with and \ncompensate government and private agencies or persons for the purpose \nof conducting research, surveys, and other services necessary to enable \nthe Board to carry out its duties.\n    (e) Investigations.--The Board may make such investigations as it \nconsiders necessary to determine whether there is or may be a violation \nof any regulation promulgated under this Act and may require or permit \nany person to file with it a statement in writing, under oath or \notherwise as the Board shall determine, as to all the facts and \ncircumstances concerning the matter to be investigated.\n    (f) Subpoena Power.--\n            (1) In general.--The Board may issue subpoenas requiring \n        the attendance and testimony of witnesses and the production of \n        any evidence relating to any matter under investigation by the \n        Board. The attendance of witnesses and the production of \n        evidence may be required from any place within the United \n        States at any designated place of hearing within the United \n        States.\n            (2) Failure to obey a subpoena.--If a person refuses to \n        obey a subpoena issued under paragraph (1), the Board may apply \n        to a United States district court for an order requiring that \n        person to appear before the Board to give testimony, produce \n        evidence, or both, relating to the matter under investigation. \n        The application may be made within the judicial district where \n        the hearing is conducted or where that person is found, \n        resides, or transacts business. Any failure to obey the order \n        of the court may be punished by the court as civil contempt.\n            (3) Service of subpoenas.--The subpoenas of the Board shall \n        be served in the manner provided for subpoenas issued by a \n        United States district court under the Federal Rules of Civil \n        Procedure for the United States district courts.\n            (4) Service of process.--All process of any court to which \n        application is made under paragraph (2) may be served in the \n        judicial district in which the person required to be served \n        resides or may be found.\n\nSEC. 8. ASSISTANCE FOR THE BOARD.\n\n    The Director of the National Institutes of Health, the Commissioner \nof the Food and Drug Administration, and the Director of the Center for \nDisease Control shall report to the Board the amount of any subsidy \npaid through such agency to a patentee.\n\nSEC. 9. REPORT.\n\n    Not later than 1 year after the initial meeting of the Board under \nsection 3(e), and annually thereafter, the Board shall submit to the \nCongress a report describing the activities of the Board for the \npreceding year."
}